Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q2 2026 Earnings Call Transcript
VIR - Vir Biotechnology, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.75
DETAILS
HIGH:
$30.00
LOW:
$20.00
MEDIAN:
$22.50
CONSENSUS:
$23.75
UPSIDE:
141.73%
Stock News
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology (NASDAQ: VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500. The company ended the quarter with approximately $1.01 billion in cash, cash equivalents and
Vir Biotechnology Q2 Earnings Call Highlights
Vir Biotechnology NASDAQ: VIR reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer candidate VIR-5500.
Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates
Vir Biotechnology, Inc. (VIR) came out with quarterly earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to a loss of $0.8 per share a year ago.
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. “This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts emphasized that achieving durable suppression of hepatitis delta virus to undetectable levels is a key predictor of improved clinical outcomes for people with CHD. Our.
Vir Biotechnology Announces Chief Financial Officer Transition
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Princi
Vir Biotechnology Announces Chief Financial Officer Transition
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O'Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep in.
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powe.
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has partnered with Astellas Pharma to develop VIR-5500, its masked PSMA-targeting T-cell engager for prostate cancer. Updated data from VIR-5818 are due in H2'26 and could include a further ~18 months of data.
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. “We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. “Tim brings a strong background of strategic discipline and operational insight that has he.
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chronic hepatitis delta virus infection: Week 96 endpoint results from the Phas.
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, underserved market with potential for high margins and accelerated regulatory approval. The Astellas partnership secures funding for oncology development, extends the cash runway into 2028, and minimizes dilution risk ahead of key catalysts.
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered incredible momentum during the first quarter with positive, new VIR-5500 Phase 1 data and execution of a global agreement with Astellas in prostate cancer. The closing of our collaboration with Astellas in April has ignited the next stage of development work, bolstering our ability to move faster an.
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12 at 4:20 p.m. PT / 7:20 p.m. ET in Las Vegas, Nevada. A live webcast of the fireside chat will be available at https://investors.vir.bio and will be archived for 30 days. About Vir Biotechnology Vir Biotechnology, Inc. is a clin.
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate update and discuss its financial results for the first quarter ended March 31, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website. About Vir Biotechnology Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on pow.
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The collaboration aims to accelerate the development of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) for metastatic prostate cancer. S.
Price Targets
Vir Biotechnology price target lowered to $25 from $27 at Morgan Stanley
$25.00
(was $9.11)
Morgan Stanley
Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley
$27.00
(was $8.25)
Morgan Stanley
Vir Biotechnology price target lowered to $23 from $24 at Morgan Stanley
$23.00
(was $9.38)
Morgan Stanley
Vir Biotechnology (VIR) PT Raised to $20 at H.C. Wainwright
$20.00
(was $9.13)
Patrick Trucchio
·
H.C. Wainwright
Vir Biotechnology (VIR) PT Raised to $20 at Leerink Partners
$20.00
(was $9.32)
Roanna Ruiz
·
Leerink Partners
Vir Biotechnology price target raised to $30 from $26 at Barclays
$30.00
(was $9.49)
Barclays
Vir Biotechnology price target raised to $18 from $12 at Evercore ISI
$18.00
(was $9.70)
Cory Kasimov
·
Evercore ISI
Vir Biotechnology (VIR) PT Raised to $18 at Needham
$18.00
(was $9.64)
Joseph Stringer
·
Needham
Vir Biotechnology price target raised to $24 from $20 at Morgan Stanley
$24.00
(was $7.43)
Michael Ulz
·
Morgan Stanley
Raymond James Upgrades Vir Biotechnology (VIR) to Strong Buy
$19.00
(was $9.69)
Sean McCutcheon
·
Raymond James
Vir Biotechnology price target raised to $26 from $24 at Barclays
$26.00
(was $7.47)
Barclays
Vir Biotechnology price target lowered to $24 from $31 at Barclays
$24.00
(was $7.68)
Etzer Darout
·
Barclays
H.C. Wainwright Reiterates Buy Rating on Vir Biotechnology (VIR)
$15.00
(was $5.98)
Patrick Trucchio
·
H.C. Wainwright
Vir Biotechnology initiated with an Outperform at Raymond James
$12.00
(was $5.65)
Sean McCutcheon
·
Raymond James
Vir Biotechnology upgraded to Overweight from Equal Weight at Morgan Stanley
$20.00
(was $7.89)
Michael Ulz
·
Morgan Stanley
Vir Biotechnology price target raised to $28 from $27 at Barclays
$28.00
(was $9.73)
Gena Wang
·
Barclays
Vir Biotechnology (VIR) PT Raised to $15 at Morgan Stanley
$15.00
(was $12.66)
Michael Ulz
·
Morgan Stanley
Barclays Reiterates Overweight Rating on Vir Biotechnology (VIR)
$27.00
(was $9.69)
Gena Wang
·
Barclays
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
$28.38
(was $25.74)
Paul Choi
·
Goldman Sachs
Vir Biotechnology (VIR) Stock: $35 Price Target And Buy Rating
$35.00
(was $21.87)
Joseph Stringer
·
Needham